<DOC>
	<DOCNO>NCT02578693</DOCNO>
	<brief_summary>The study design provide long term clinical virologic follow subject infect hepatitis C virus ( HCV ) receive interferon-based therapy direct-acting antiviral agent ( DAAs ) -based therapy . This long term follow study observational treatment provide HCV infection .</brief_summary>
	<brief_title>Follow IFN Vs DAAs HCV SVR ( IFDACS Study )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Patients chronic hepatitis C treat interferonbased therapy directacting agent ( DAAs ) base regimen ; Provide write , informed consent ; Be willing able comply visit schedule protocolmandated procedure . Individuals plan start new course hepatitis C therapy include investigational drug device course followup time frame ; History clinically significant illness major medical disorder may interfere follow , assessment , compliance protocol . Inability provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>